Canadian Institute For Knowledge Development
  • Register
  • Login

Canadian Journal of Medicine

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 3, Issue Issue 3
  3. Authors

Current Issue

By Issue

By Subject

Keyword Index

Author Index

Indexing Databases XML

About Journal

Aims and Scope

Editorial Board

Indexing and Abstracting

Peer Review Process

News

An Evaluation of the Potential of Heparin to Inhibit the Viral Entry of SARS-CoV-2

    Sudipta Samadder Peter Anto Johnson John Christy Johnson Austin Mardon

Canadian Journal of Medicine, 2021, Volume 3, Issue Issue 3, Pages 147-152
10.33844/cjm.2021.60513

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Heparin is an anticoagulant medicine that prevents the formation of harmful blood clots in the vessels. Following the outbreak of the novel coronavirus disease 2019 (COVID-19), heparin has helped to improve the health of affected patients beyond its anticoagulant effects. The potential antiviral activity of heparin has attracted speculation due to its highly sulfated profile, which allows it to have a high binding affinity to a wide range of viral components. Heparin’s successful binding to the ZIKA virus, human immunodeficiency virus, as well as the SARS CoV and MERS CoV spike proteins have demonstrated its potential to inhibit the entry of SARS-CoV-2 into the body. A high degree of sequence homology also enables heparin to have inhibitory binding potential on viral components. The SARS-CoV-2 virus exhibits significant differences in its spike glycoprotein (SGP) sequence compared to other coronaviruses. The SGP sequence in SARS-CoV-2 contains additional potential glycosaminoglycan (GAG) binding domains that may drive differences in the attachment and entry process of the virus. Findings from unbiased computational ligand docking simulations, pseudotyped spike protein experiments, and cell to cell fusion assays have also opened possibilities to investigate the antiviral properties of heparin in clinical trials
Keywords:
    Heparin SARS-CoV-2. Polysaccharide COVID-19 Glycosaminoglycans Inhibition
  • PDF (337 K)
  • XML
(2021). An Evaluation of the Potential of Heparin to Inhibit the Viral Entry of SARS-CoV-2. Canadian Journal of Medicine, 3(Issue 3), 147-152. doi: 10.33844/cjm.2021.60513
Sudipta Samadder; Peter Anto Johnson; John Christy Johnson; Austin Mardon. "An Evaluation of the Potential of Heparin to Inhibit the Viral Entry of SARS-CoV-2". Canadian Journal of Medicine, 3, Issue 3, 2021, 147-152. doi: 10.33844/cjm.2021.60513
(2021). 'An Evaluation of the Potential of Heparin to Inhibit the Viral Entry of SARS-CoV-2', Canadian Journal of Medicine, 3(Issue 3), pp. 147-152. doi: 10.33844/cjm.2021.60513
An Evaluation of the Potential of Heparin to Inhibit the Viral Entry of SARS-CoV-2. Canadian Journal of Medicine, 2021; 3(Issue 3): 147-152. doi: 10.33844/cjm.2021.60513
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 561
  • PDF Download: 292
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap
Powered by eJournalPlus